Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1645 1646
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18124096 | PURIFICATION OF MULTISPECIFIC ANTIBODIES | Non-Final OA | GENENTECH, INC. |
| 18042267 | ANTIGEN BINDING PROTEINS WITH NON-CANONICAL DISULFIDE IN FAB REGION | Non-Final OA | AMGEN INC. |
| 18051307 | PREDICTING RESPONSE TO PD-1 AXIS INHIBITORS | Final Rejection | Hoffmann-La Roche Inc. |
| 17937440 | BISPECIFIC ANTIBODIES COMPRISING A MODIFIED C-TERMINAL CROSSFAB FRAGMENT | Final Rejection | Hoffmann-La Roche Inc. |
| 19242715 | COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE | Non-Final OA | Viridian Therapeutics, Inc. |
| 18364620 | COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE | Non-Final OA | Viridian Therapeutics, Inc. |
| 16435257 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | Final Rejection | The Trustees of the University of Pennsylvania |
| 18268840 | EFFECTORLESS FC MOLECULES | Non-Final OA | SANOFI |
| 17481578 | SERUM ALBUMIN-BINDING IMMUNOGLOBULIN VARIABLE DOMAINS | Final Rejection | Sanofi |
| 17907781 | SELECTIVE MODULATION OF TRANSFORMING GROWTH FACTOR BETA SUPERFAMILY SIGNALING VIA MULTI-SPECIFIC ANTIBODIES | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 18365239 | FUSION PROTEIN BASED ON SINGLE-CHAIN ANTIBODY FRAGMENT, NANO-ASSEMBLY, AND PREPARATION METHODS THEREFOR AND APPLICATIONS THEREOF | Non-Final OA | SOUTH CHINA UNIVERSITY OF TECHNOLOGY |
| 18018864 | MULTISPECIFIC BINDING AGENTS AND USES THEREOF | Final Rejection | EXELIXIS, INC. |
| 17929874 | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION | Non-Final OA | Vellera Therapeutics Inc. |
| 18346975 | ANTI-HLA-DQ2.5 ANTIBODY AND ITS USE FOR THE TREATMENT OF CELIAC DISEASE | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17914432 | METHOD FOR PRODUCING MULTISPECIFIC ANTIGEN-BINDING MOLECULES | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 16692676 | ANTIGEN-BINDING MOLECULE HAVING REGULATED CONJUGATION BETWEEN HEAVY-CHAIN AND LIGHT-CHAIN | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 18029525 | METHODS OF TREATING DERMATOMYOSITIS | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 17926283 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES | Final Rejection | MERUS N.V. |
| 17755196 | MEANS AND METHODS FOR TREATING SUBJECTS WITH HER2 AND HER3 POSITIVE CANCER | Non-Final OA | Merus N.V. |
| 17720954 | ANTI-CD27 AND ANTI-PD-L1 ANTIBODIES AND BISPECIFIC CONSTRUCTS | Non-Final OA | Celldex Therapeutics, Inc. |
| 18155740 | CD3 BINDING ANTIBODIES | Final Rejection | TeneoBio, Inc. |
| 17762463 | BINDING MODULES COMPRISING MODIFIED EHD2 DOMAINS | Final Rejection | UNIVERSITÄT STUTTGART |
| 18250347 | RECOMBINANT T-CELL RECEPTORS THAT BIND THE NY-ESO-1 AND/OR LAGE-1A CANCER ANTIGENS | Non-Final OA | T-Cure Bioscience, Inc. |
| 18463194 | ANTI-PD-L1 ANTIBODIES | Non-Final OA | IGM Biosciences, Inc. |
| 18239052 | Multi-Specific Molecules | Non-Final OA | IMUNEXUS THERAPEUTICS LIMITED |
| 18453107 | COMBINED THERAPEUTIC USE OF ANTIBODIES AND IMMUNOGLOBULIN G-DEGRADING ENZYMES | Non-Final OA | Hansa Biopharma Limited |
| 18450995 | CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO | Non-Final OA | Johannes Gutenberg-Universität Mainz |
| 17822959 | NOVEL ANTIBODY FRAMEWORKS | Non-Final OA | Numab Therapeutics AG |
| 17922230 | ANTIGEN BINDING CONSTRUCTS TARGETING HER2 AND USES THEREOF | Final Rejection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| 18320599 | TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | Non-Final OA | MacroGenics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy